If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
130
results.
Updated on
05/11/2025 [07:07:00]
Results 25 to 50 of 130
Absstract of: US2025325547A1
The present invention relates to a compound represented by formula (I), a salt thereof, a solvate thereof, or a prodrug thereof, and an anti-SARS-CoV-2 drug having the same:wherein R1, R2, and R3 are the same or different, and each of them is a hydrogen atom, a halogen atom, a substituted or unsubstituted C1-6-alkyl group, a substituted or unsubstituted C1-6-alkoxy group, or —N(Ra)(Rb) wherein Ra and Rb are the same or different, and each of them is a substituted or unsubstituted C1-10-alkyl group or a substituted or unsubstituted aryl group; or Ra and Rb, together with an adjacent nitrogen atom, may form a substituted or unsubstituted 5 to 7-membered ring,R4 is —N(Ra)(Rb) wherein Ra and Rb are the same or different, and each of them is a substituted or unsubstituted C1-10-alkyl group or a substituted or unsubstituted aryl group; or Ra and Rb, together with an adjacent nitrogen atom, may form a substituted or unsubstituted 5 to 7-membered ring,X is a hydrogen atom, a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom, andthe hydroxyl group in the formula may be substituted with a protecting group.
Absstract of: US2025327142A1
Described herein are methods for the detection of a virus (e.g., SARS-CoV-2) RNA in dust, which can be used for continued environmental surveillance of the viral disease. Targeted monitoring of dust in high-concern buildings can complement broader population-level monitoring approaches. Additionally, a method for detection of a viral RNA in a dust sample is disclosed herein.
Absstract of: US2025325653A1
Engineered SARS-CoV-2 variants having a combination of attenuating modifications, and their use as live-attenuated SARS-CoV-2 vaccines, are described. The recombinant genome of the live-attenuated SARS-CoV-2 encodes a modified spike (S) protein with a deletion of the polybasic site (ΔPRRA); encodes a modified non-structural protein 1 (Nsp1) with K164A and H165A substitutions; and includes a mutation that prevents expression of open reading frames (ORFs) 6, 7a, 7b and 8. The disclosed live-attenuated SARS-CoV-2 retain the capacity to infect and replicate in mammalian cells. Immunogenic compositions that include a live-attenuated SARS-CoV-2 and methods of eliciting an immune response against SARS-CoV-2 in a subject are also described. Further disclosed are a collection of reverse genetics plasmids that include the complement of the recombinant genome of the live-attenuated SARS-CoV-2 and methods of producing a live-attenuated SARS-CoV-2 using the reverse genetics plasmids.
Absstract of: US2025325672A1
The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), particularly the spike protein S1 of SARS-COV-2. The invention also includes pharmaceutical compositions comprising said polypeptides and to the use of said polypeptides in suppressing or treating a disease or disorder mediated by infection of SARS-COV-2 or for providing prophylaxis to a subject at risk of infection of SARS-COV-2.
Absstract of: US2025325648A1
Described herein is a replicative Vesicular stomatitis virus (rVSV) comprising: a first Filoviridae glycoprotein comprising one or more influenza virus matrix 2 ectodomain peptide inserted into the first Filoviridae glycoprotein; and a second Filoviridae glycoprotein comprising a SARS-CoV2 Spike protein peptide inserted into the second Filoviridae glycoprotein, or a first Filoviridae glycoprotein comprising one or more influenza virus matrix 2 ectodomain peptide inserted into the first Filoviridae glycoprotein and a non-functional but immunogenic SARS-CoV2 Spike protein. The Spike protein or Spike protein peptide can be derived from different CoV-2 variants. The rVSV can be used as a Dual Action vaccine for vaccinating individuals simultaneously against both influenza virus and SARS CoV2 virus.
Absstract of: AU2023395159A1
The present technology provides multivalent vaccine compositions and Tcell compositions comprising viral antigens and associated methods. In some embodiments, the viral antigens are SARS-CoV-2 antigens. The vaccine compositions and the T cell compositions may comprise each of a Spike (S) peptide, a VME1 (M) peptide, an NCAP (N) peptide, an ORF7a (7a) peptide, an ORF3a (3a) peptide, an ORF8 (8) peptide, and an Nsp6 peptide.
Absstract of: US2025319181A1
A pheromonicin against SARS-COV-2. Antibody mimetics, i.e., two 28-residues are designed for the first time by selecting the E protein and M protein of SARS-COV-2, which are relatively conserved and have low probability of mutation, as targets. Pharmacodynamic experiments performed using three SARS-COV-2 strains (the epidemic strain GD108, the South Africa strain SA and the India strain IND) respectively prove that fusion proteins obtained by linking the 28-residues to colicin can provide effective protective efficacy against pulmonary lesions induced by SARS-COV-2, and can be used as drugs for treating and preventing SARS-COV-2.
Absstract of: US2025319060A1
The present invention recognizes that there is a need for the prophylaxis or treatment of COVID and COVID-19. A first aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using various pharmaceutical compositions. A second aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using combinations of antimalarial drugs and antiviral drugs. A third aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using nanoparticle formulations that include pharmaceutical compositions. A fourth aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using combinations of various pharmaceutical compositions. A fifth aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using a polio vaccine and pharmaceutical compositions.
Absstract of: US2025319176A1
The present invention provides constructs of the parainfluenza virus type-5 (PIV5) virus expressing the SARS-CoV-2 envelope spike (S) protein for use as safe, stable, efficacious, and cost-effective vaccines against COVID-19.
Absstract of: AU2024253607A1
An immunogenic composition for inducing immune responses against both influenza and coronaviruses includes: (a) a coronavirus S (CoV S) glycoprotein in the form of a detergent-core nanoparticle, wherein the detergent is a non-ionic detergent; (b) at least three hemagglutinin (HA) glycoproteins, wherein each HA glycoprotein is from a different influenza strain; and (c) a pharmaceutically acceptable buffer. An immunogenic composition for inducing immune response against influenza includes: (a) at least three hemagglutinin (HA) glycoproteins, wherein each HA glycoprotein is from a different influenza strain, wherein from 30 to 60 µg of HA per strain is present in the composition; and (b) a pharmaceutically acceptable buffer. The immunogenic compositions may include an adjuvant. Methods of stimulating an immune response against SARS-CoV-2, a heterogeneous SARS-CoV-2 strain, an influenza virus, or a combination thereof include the administration of the immunogenic compositions.
Absstract of: AU2025234176A1
The present invention relates to novel methods comprising the administration of pentosan polysulfate for treating or preventing coronavirus infection and cytokine- associated toxicity, including cytokine toxicity resulting from aberrant activation of the immune system in coronavirus disease or infection, such as those from SARS-CoV-2. 5 The present invention relates to novel methods comprising the administration of pentosan polysulfate for treating or preventing coronavirus infection and cytokine- associated toxicity, including cytokine toxicity resulting from aberrant activation of the 5 immune system in coronavirus disease or infection, such as those from SARS-CoV-2. ep h e p r e s e n t i n v e n t i o n r e l a t e s t o n o v e l m e t h o d s c o m p r i s i n g t h e a d m i n i s t r a t i o n o f e p p e n t o s a n p o l y s u l f a t e f o r t r e a t i n g o r p r e v e n t i n g c o r o n a v i r u s i n f e c t i o n a n d c y t o k i n e - a s s o c i a t e d t o x i c i t y , i n c l u d i n g c y t o k i n e t o x i c i t y r e s u l t i n g f r o m a b e r r a n t a c t i v a t i o n o f t h e i m m u n e s y s t e m i n c o r o n a v i r u s d i s e a s e o r i n f e c t i o n , s u c h a s t h o s e f r o m - o -
Absstract of: US2025319125A1
The present application discloses neutralizing anti-SARS-COV-2 antibodies or antigen-binding fragments thereof that are effective against several SARS-COV-2 variants. Pharmaceutical compositions comprising the antibodies or antigen-binding fragments thereof are also disclosed. The antibodies, antigen-binding fragments thereof, or pharmaceutical compositions described herein may be used for the prevention and/or treatment of coronavirus infection and/or associated diseases and symptoms, such as SARS-COV-2 infection and/or COVID-19.
Absstract of: US2025320246A1
Compounds of formula (I):wherein R1, R2 and R3 are as defined herein are able to rescue dysfunctional mitochondria and are therefore of use in the treatment and prevention of neurodegenerative disorders as well as acute radiation syndrome and myalgic encephalomyelitis (ME, chronic fatigue syndrome) or post viral syndrome, including chronic symptoms arising from infection with SARS-CoV2 (long COVID).
Absstract of: US2025320308A1
The present invention provides for monoclonal anti-IFITM2 and anti-IFITM3 antibodies or a fragment thereof, pharmaceutical compositions comprising said antibodies and its use in the treatment of viral infections, preferably of SARS-COV-2 infection in host human cells.
Absstract of: US2025320255A1
Self-adjuvanting vaccine compositions comprising at least one modified immunogen via in vitro glycosylation methods that provide a rational approach for generating glycosylated versions of immunogens via the reducing end of a linear carbohydrate, the reducing end containing an N-acyl-2-amino moiety. Self-adjuvanting vaccine compositions comprising a plurality of heterologous immunogens associated with a multivalent carrier, wherein at least one immunogen is glycosylated to allow for mucosal delivery. Self-adjuvanting vaccine compositions comprising multivalent carriers and related methods using the self-adjuvanting vaccine compositions in various therapeutic and prophylactic applications for inducing an immune response against, treating, or preventing a bacterial, viral, fungal, or protozoan infection. Pathogens for which this approach may be useful include, but are not limited to, influenza viruses, rhinoviruses, human immunodeficiency viruses (HIV), respiratory syncytial virus (RSV), coronaviruses, Babesia, Borrelia, Neisseria, and Chlamydia, and the related diseases thereof.
Absstract of: US2025320278A1
Compositions and methods are disclosed for diagnosing, treating, and/or preventing coronavirus infection and related pathologies. The compositions include antibodies having certain defined heavy and light chain sequences that recognize the coronavirus nucleoprotein or mutants thereof. In embodiments, the coronavirus is SARS-CoV-2
Absstract of: US2025318951A1
A method for treating viral infections caused by viruses whose survival time depends on temperature (e.g., cold viruses, flu viruses, COVID-19, etc.) is based on administrating to a subject an effective amount of thermal energy transferred from a hotter liquid product to the colder subject using a predetermined combination of the temperature of the liquid product, the duration of time of supplying the liquid product, and the amount of the liquid product. This method of treatment inactivates viruses in the upper respiratory tract and gastrointestinal tract of the subject and enhances the response of the immune system, thereby preventing complications and accelerating the recovery of the infected subject.
Absstract of: WO2025214462A1
A multispecific antibody or an antigen-binding molecule thereof, a homodimer thereof, a nucleic acid molecule encoding the multispecific antibody or the antigen-binding molecule thereof, a vector comprising the nucleic acid molecule, a host cell comprising the vector, a recombinant protein or immunoconjugate comprising the multispecific antibody or the antigen-binding molecule thereof, a use thereof in the preparation of a medicament for treating or preventing respiratory tract infections caused by viruses or in the preparation of a medicament for treating or preventing respiratory tract inflammation or dermatitis, and in a detection product. The multispecific antibody or the antigen-binding molecule thereof has excellent broad-spectrum neutralizing capability for coronaviruses and significant neutralizing capacity for coronavirus mutant strains, especially a variety of SARS-CoV-2 coronavirus mutant strains including Omicron subvariants BQ.1.1, XBB.1.5, XBB.1.16, EG.5, BA.2.86, and JN.1. The multispecific antibody or the antigen-binding molecule thereof can not only treat or prevent respiratory tract infection symptoms caused by viruses but also significantly relieve respiratory tract inflammation responses. The multispecific antibody or the antigen-binding molecule thereof has a good therapeutic effect on inflammatory diseases such as rhinitis, asthma, and dermatitis and has good clinical application prospects in the future.
Absstract of: US2025319160A1
The present invention relates to pharmaceutical compositions comprising an mRNA encoding an IFN-λ polypeptide for use in treating a viral-induced disorder, preferably a viral-induced respiratory disorder, such as COVID-19.
Absstract of: US2025319197A1
This invention provides compositions and methods to treat, prevent, and diagnose viral infections. The methods provided herein involve administering polypeptides of the invention to a subject in need thereof. The viral infections can be caused by a coronavirus such as SARS-COV-1, SARS-COV-2 or a variant thereof. It is contemplated that the polypeptide can be further linked to a compound, wherein the compound extends the serum half-life of the polypeptide.
Absstract of: EP4631574A2
This present invention relates to the use of eicosapentaenoic acid (EPA) for treating and reducing the negative effects of respiratory virus including coronaviruses and particularly the novel coronavirus-19 (COVID-19). Notably, the eicosapentaenoic acid in the free fatty acid (EPA-FFA) form has a purity of at least has a purity of at least 90%, preferably 95% and more preferably at least 99%. Specifically, the EPA-FFA exhibits a reduction of expressed interleukins, such as IL-6, reduction in D-dimers and a reduction relating to the release of AA.
Absstract of: WO2024124241A2
This disclosure generally relates to humanized antibodies and their therapeutic use. More specifically, this disclosure is in the field of producing humanized antibodies that are optimized for biological and chemical features, including acitivies against SARS-CoV-2 variants, such as omicron variants.
Absstract of: AU2024227880A1
The present disclosure provides ACE2 fusion proteins, comprising multimerization moieties linked to ACE2 moieties, that specifically bind to RBD regions of SARS-CoV and/or SARS-CoV-2. The present disclosure further relates to the methods of producing the ACE2 fusion proteins, pharmaceutical compositions comprising of the ACE2 fusion proteins, and methods of use of the ACE2 fusion proteins to treat conditions associated with SARS-CoV and SARS-CoV-2 infections, such as COVID-19.
Absstract of: AU2024229916A1
The present disclosure provides multivalent anti-spike protein binding molecules, comprising multimerization moieties linked to anti-spike protein antigen-binding domains, that specifically bind to RBD regions of SARS-CoV and/or SARS-CoV-2. The present disclosure further relates to the methods of producing the multivalent anti-spike protein binding molecules, pharmaceutical compositions comprising of the multivalent anti-spike protein binding molecules, and methods of use of the multivalent anti-spike protein binding molecules to treat conditions associated with SARS-CoV and SARS-CoV-2 infections, such as COVID-19.
Nº publicación: US2025312370A1 09/10/2025
Applicant:
ADENYLATE THERAPEUTICS LLC [US]
ADENYLATE THERAPEUTICS LLC
Absstract of: US2025312370A1
Treatments for SARS-CoV-2 infection, COVID-19, symptoms of COVID-19, and similar infections. Specifically, treatments for patients identified as having Acute Respiratory Distress Syndrome (ARDS), and specifically COVID-19 ARDS, and/or suffering the effects of hypoxia. The treatments include increasing a patient's naturally occurring levels of ATP, adenosine, and/or other adenosine compounds.
BOPI
Electronic site
